Retatrutide (GLP-1/GIP/GCGR) 15mg

Retatrutide, a GLP-1/GIP/GCGR receptor agonist Research Topics:

1. Glycemic Control:

   Retatrutide effectively lowers blood glucose levels by enhancing insulin secretion and reducing glucagon secretion, beneficial for managing type 2 diabetes (PMID: 38356208).

2. Weight Loss:

   It promotes substantial weight loss, with phase 2 trials showing a placebo-subtracted weight loss ranging from 6.6% to 22.1%, and up to 48% of participants losing more than 25% of their baseline weight (PMID: 37366315).

3. Cardiovascular Benefits:

   Retatrutide helps reduce the risk of major cardiovascular events, providing cardiovascular protection (PMID: 37902090).

4. Improved Metabolic Health:

   It enhances overall metabolic health by improving insulin sensitivity and lipid metabolism (PMID: 38356208).

Related Research

The differences in weight loss percentages for Semaglutide (GLP-1), Tirzepatide (GLP-1/GIP), and Retatrutide (GLP-1/GIP/GCGR) are as follows:

1. Semaglutide (GLP-1):

   In clinical trials, Semaglutide resulted in a weight loss of approximately 12% over a period of 68 weeks (PMID: 32910488).

2. Tirzepatide (GLP-1/GIP):
   

   Tirzepatide demonstrated a weight loss ranging from 15% to 21% in different studies over a period of 72 weeks (PMID: 32910487).

3. Retatrutide (GLP-1/GIP/GCGR):

   In a phase 2 trial, Retatrutide showed a placebo-subtracted weight loss ranging from 6.6% to 22.1% over 48 weeks (PMID: 37366315).

Peer-Reviewed Studies

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial

Ania M Jastreboff, Lee M Kaplan, Juan P Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Milicevic, Mark L Hartman; Retatrutide Phase 2 Obesity Trial Investigators, Clinical Trial, N Engl J Med, 389(6):514-526. doi: 10.1056/NEJMoa2301972

• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Julio Rosenstock, Juan Frias, Ania M Jastreboff, Yu Du, Jitong Lou, Sirel Gurbuz, Melissa K Thomas, Mark L Hartman, Axel Haupt, Zvonko Milicevic, Tamer Coskun, Clinical Trial, Lancet, 402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X.

Retatrutide Structure

Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3 Molecular Formula: C223H343F3N45O10
Molecular Weight: 4845.44 g/mol
PubChem SID: 474492335
CAS Number: 2381089-83-2
Synonyms: L Y-3437943, NOP2Y096GV